Prior authorization required for listed product codes

Obtain prior authorization per payer process for the specific HCPCS/CPT/product codes listed in the policy before billing; inclusion of a product in coding tables does not itself establish medical necessity.

• Examples of listed codes include Q4116, Q4100, Q4122, Q4128, Q4130, C9358, C9360 and CPT codes 15011–15018.

Prior authorization and code-based utilization limits

When product-specific HCPCS codes are used, obtain prior authorization consistent with the utilization limits in each product section (initial application limits and maximum total applications within a 12‑week episode).

• Example limits: AlloPatch (Q4128) — initial ≤5 applications; up to 8 applications per ulcer within 12 weeks. Dermagraft (Q4431) — initial ≤5; up to 8 in 12 weeks. Many products: initial 1 and up to 4–5 applications in 12 weeks depending on product.
• Applications beyond 12 weeks per ulcer are not medically necessary.

Prior authorization may be required per CMS/LCD

Confirm whether CMS NCDs/LCDs or local coverage articles apply and obtain prior authorization when required by those determinations or by the member's plan.

• MAC/LCD/NCD guidance takes precedence; check the Medicare Coverage Database and the member's plan documents.

Prior authorization for adjunctive skin substitute use

Obtain prior authorization for adjunctive skin substitute use when the policy requires the product to be used only after failure of optimized standard care and when product-specific indications include adjunctive use.

• Document prior conservative management (debridement, dressings, infection control, offloading for DFU or compression for VLU) when submitting the authorization request.

Include FDA product/clearance identifiers in PA submissions

Reference the FDA product/clearance identifiers and device names listed in the regulatory sections when submitting prior authorization or coverage review documentation for a specific product.

• Examples of FDA identifiers in the policy: P950032A, K061711, P000036A, P900033/s042, BP170122.

FDA device identifiers for PA verification

Use the FDA PMA/510(k)/HCT/P numbers provided in the policy to help verify product regulatory status during prior authorization review.

• Cite identifiers such as P950032A (Apligraf), K061711 (Oasis), P000036A (Dermagraft), and P900033 variants when relevant.

Regulatory listings do not by themselves require PA

This regulatory listing section enumerates FDA identifiers for products and does not impose additional prior authorization requirements by itself.

• Regulatory listings are informational; prior authorization requirements are described elsewhere in the policy or by the payer.

No PA rule stated in regulatory listing

The regulatory identifier tables provide FDA clearance/approval numbers and product names but do not specify prior authorization rules; use them for verification only.

• Providers should not assume authorization requirements from these listings alone.

FDA clearance references (informational)

FDA clearance references and identifiers are listed for provider reference; they support verification during utilization review but do not establish prior authorization criteria.

• Documented examples include K112409, K172399, and K132343 among others.

Regulatory listing — PA not specified here

Regulatory product identifiers are listed for reference; the policy's regulatory listings do not themselves mandate prior authorization.

• Use these identifiers when validating product clearance during PA or claims review.

Prior authorization and correct billing for application/product

Obtain any required prior authorization before billing skin substitute application and related product codes; ensure the application code and product code are billed together on the same claim for the same date of service.

• Application codes (e.g., 15271–15278, G0681–G0684) must be billed on same claim with product HCPCS/CPT codes.
• Follow payer prior authorization process when required.

Report exact product HCPCS/CPT and follow add-on instructions

Bill the exact HCPCS/CPT product code(s) that correspond to the product used and follow add-on/list-separately instructions where noted in the coding section.

• Many product HCPCS (Q-codes) are designated add-on and must be listed separately in addition to the primary procedure.

Use mapped Q-code for add-on/excluded products

When a product is designated as an add-on or excluded item in the policy, bill the mapped Q-code and list it in addition to the primary procedure; do not bill it as a standalone primary procedure.

• Examples of add-on Q-codes are Q4168 through Q4326; follow the policy mapping when billing.

PA may be required — submit medical necessity documentation

Prior authorization may be required for certain products or procedures; when required, submit documentation demonstrating medical necessity and follow the plan's prior authorization process.

• Individual case review with prior plan approval is required for investigational or unproven treatments.

When PA is required, obtain plan approval with supporting documentation

If prior authorization is required, providers must submit requests showing medical necessity and obtain plan approval; individual case review may allow coverage for investigational treatments with prior approval.

• Decisions for investigational treatments are made by a Priority Health medical director or clinical pharmacist.

Document ≥4 weeks failed standard care (≥50% area reduction threshold)

Document and demonstrate failure of an adequate trial of standard wound care (e.g., wound failed to show ≥50% area reduction after ≥4 weeks of documented standard care) before requesting advanced skin substitute therapy.

• Standard care components include debridement when indicated, appropriate dressings, infection assessment/management, and etiology-specific measures (offloading for DFU; compression for VLU).

Adjunctive use only — document standard care and rationale

Use skin substitutes only as adjuncts after an adequate trial of standard wound care (debridement, dressings, infection control, and etiology-specific therapy) and document the rationale for adjunctive product selection.

• Adjunctive use must not replace foundational therapy (e.g., offloading or sustained compression).

Stepwise escalation — optimize foundational care before advanced products

Follow a stepwise escalation strategy: optimize etiology-specific standard care (e.g., compression for VLUs; offloading for DFUs) and escalate to product-specific adjunctive therapies only when wounds fail to progress.

• Consider RCT-proven advanced agents for chronic DFUs that fail to heal with optimal standard care.

Maintain optimized etiology-specific standard care before application

Optimize and continue etiology-specific standard care (compression for VLUs; offloading and diabetes management for DFUs) before and during adjunctive skin substitute therapy.

• For DFU, ensure offloading is maintained and HbA1c assessment and diabetes optimization are documented.

Regulatory listing — no step therapy rules here

This regulatory listing chunk is informational and does not impose step therapy or authorization actions; consult the clinical criteria sections for required prerequisites.

• Regulatory identifiers here are for provider reference only.

Regulatory listings — no PA or step therapy specified

Regulatory identifier listings in this section are informational; they do not specify provider actions or authorization steps.

• Use identifiers for verification, but follow clinical criteria elsewhere in the policy.

Check plan-level requirements and member benefits

Plan- or group-specific documents may impose additional utilization rules; verify member-specific benefits and any state-mandated provisions before requesting authorization or billing.

• For self-funded (ASO) and individual plans consult the plan document; Medicare coverage is determined by CMS when an NCD/LCD applies.

Document wound assessment, infection control, and treatment plan

Include the following clinical details in prior authorization and chart documentation: wound depth, total body surface area (when relevant), anatomic location, functional risk areas, wound bed status and infection control, and a treatment plan explaining why standard therapy alone is insufficient.

• For burns include TBSA, burn depth, and donor-site considerations; for ulcers include serial wound measurements and healing trajectory.

DFU-specific documentation: diabetes status, HbA1c, offloading

For DFU prior authorizations and charting, document diabetes type, recent HbA1c (within 90 days), evidence that diabetes management is being optimized, and that effective offloading is in place.

• Policy requires HbA1c <12% within 90 days unless documentation justifies proceeding despite higher values.

Document wound depth, no exposed deep structures, and ≥4 weeks SOC adherence

Before application, document wound depth (partial/full-thickness), absence of exposed bone/tendon/muscle/joint capsule, adherence to ≥4 weeks of standard wound care, and objective perfusion assessment as applicable (palpable pulses, ABI, toe pressure/TBI).

• Record serial wound measurements and percent area change to support failure of standard care (e.g., <50% reduction after ≥4 weeks).

Document optimized standard care and vascular assessment

Document that standard wound care was optimized (debridement when indicated, infection assessment/management, moisture balance) and include objective vascular assessment (ABI, toe pressure, or TBI) and wound healing trajectory in the record.

• Include notes on offloading for DFU or sustained compression for VLU and serial percent area changes after 4 weeks.

Document diagnosis, duration, response to SOC, and product rationale

Confirm and document the diagnosis (e.g., VLU with venous disease evaluation and exclusion/assessment of arterial disease), duration and response to an adequate trial of standard care, wound measurements/serial progress, and rationale for the chosen adjunctive product when submitting prior authorization.

• For VLU include documentation of sustained compression therapy and venous evaluation.

Reference FDA identifiers for coverage and claims validation

Consult the regulatory identifier tables for FDA product identifiers when validating product regulatory status for coverage or claims submission; include matching product identifiers when available.

• Examples: P950032A (Apligraf), K061711 (Oasis), P000036A (Dermagraft).

Document product name and FDA 510(k)/PMA identifier

Document the exact product name and corresponding FDA 510(k) or PMA identifier (when applicable) in the prior authorization and claims submission to support verification.

• Policy examples: Oasis K061711; Dermagraft P000036A; Apligraf P950032A.

Include supporting ICD-10 diagnosis codes

Use the listed ICD-10 diagnosis codes to support medical necessity on authorization requests and claims when applicable to the clinical indication.

• Examples include L97.x for non-pressure chronic ulcers, I83.x for venous ulcers, and diabetes codes E10–E13 with complications.

Provide explanatory notes for unlisted/NOS skin substitute codes

When billing with an unlisted or 'NOS' skin substitute code (e.g., Q4100 or other unlisted device codes), include an explanatory note describing the product, reason for use, and relation to the primary procedure.

• Unlisted device lines should be accompanied by clinical rationale and product details to support medical necessity and coding.

Bill using policy mapping; adhere to add-on Q-code designations

Follow the policy's billing designations and Q-code mapping when submitting claims; many named products are designated 'Add-on; listed in addition to primary procedure' and must be billed accordingly.

• Failure to bill add-on items as specified may trigger claim review or denial.

Submit medical necessity evidence with PA; investigational treatments need prior approval

When prior authorization is required, submit documentation that demonstrates medical necessity; individual case review may allow coverage for investigational treatments only with prior plan approval.

• Exceptions for investigational treatments require review by a Priority Health medical director or clinical pharmacist and prior plan approval.

Denial risk: missing wound documentation

Failure to document wound characteristics, adherence to standard care, and a treatment plan prior to application may result in denial of coverage.

• Documentation prerequisite explicitly required by the policy (wound characteristics and treatment plan present prior to application).

Denial risk: inadequate trial of standard care

If an adequate trial of standard wound care (commonly ≥4 weeks; ≥4–6 weeks for VLUs) is not documented, the request may be denied for failure to meet policy prerequisites.

• Policy cites failure to demonstrate ≥50% area reduction after ≥4 weeks as a common clinical decision point for escalation.

Denial triggers: applications >12 weeks or >10 total in 12 weeks

Treatments beyond 12 weeks per ulcer or more than ten total applications per ulcer within a 12‑week episode are considered not medically necessary and may be denied.

• Multiple different substitutes concurrently or sequentially for the same ulcer without documented rationale is also not medically necessary.

CMS/LCD precedence may affect authorization and coverage

Coverage may be governed by applicable federal/state mandates and CMS NCD/LCD determinations; failure to follow those mandates or local coverage rules can trigger denials.

• Refer to the Medicare Coverage Database for current NCD/LCD/LCA guidance.

Claim denial risk: application and product codes must be billed together

Failure to bill the appropriate skin substitute application code together with the product code on the same claim for the same date of service may result in claim denial.

• Ensure application CPT/HCPCS (e.g., 15271–15278, G0681–G0684) and product HCPCS/Q-code are on the same claim and date of service.

Denial risk: non‑medically necessary items per policy

Claims for products that do not meet the policy's medical necessity criteria (including excluded, investigational, or unproven items) are not eligible for coverage and may be denied.

• Examples include prophylactic use on closed ulcers, infected/ischemic wounds not adequately treated, and routine cosmetic uses outside criteria.

Denial risk: exclusions and add-on billing must be followed

Products listed as add-on or not separately payable must be billed as add-on items (in addition to the primary procedure); incorrect submission or billing as standalone may result in denial.

• Large lists of Q-codes are designated as add-on/not separately payable; review the coding section and bill accordingly.

Denial risk for excluded Q/HCPCS codes billed incorrectly

Claim lines using Q-codes or HCPCS codes designated as add-on or not separately payable may be denied if billed incorrectly or outside the policy rules.

• Verify mapping and add-on designation before submitting claims to avoid denials.

Denial risk: investigational/experimental treatments require prior approval

Coverage determinations for investigational, experimental, or unproven treatments require individual case review and prior plan approval; absent approved exception, such treatments are generally excluded from coverage.

• Allowed exceptions are limited (e.g., terminal illness or chronic, deteriorating severe disease) and require review by a medical director or clinical pharmacist.